AKUMS DRUGS AND PHARMA L (AKUMS) financials

AKUMS DRUGS AND PHARMA L (AKUMS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Market Cap: ₹11,513Cr.
Current Price: ₹731
Stock P/E: 98.9
ROE: 4.92%
ROCE: 6.82%
Book Value: ₹154
Dividend Yield: 0.14%
52W High / Low: ₹839/409

In Jun 2026, AKUMS DRUGS AND PHARMA L (AKUMS) reported sales ₹392 Cr and net profit ₹45 Cr.

Annual TTM: sales ₹1,409 Cr, net profit ₹112 Cr.

Shareholding: Promoters 75.26% (Sep 2026), FIIs 4.50% (Sep 2026), DIIs 11.09% (Sep 2026), Public 6.42% (Sep 2026), Others 2.73% (Sep 2026).

AKUMS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	328	337	329	332	309	369	338	392
Expenses	285	303	311	288	292	344	327	344
Operating Profit	43	34	18	44	17	25	12	49
OPM %	13%	10%	5%	13%	5%	7%	3.5%	12%
Other Income	32	34	32	29	27	26	25	26
Interest	4	2	3	3	2	2	3	2
Depreciation	9	11	10	10	11	12	12	13
Profit before tax	62	55	37	60	31	36	22	59
Tax %	18%	25%	26%	25%	25%	22%	30%	24%
Net Profit	50	41	28	45	23	28	15	45
EPS in Rs	3.20	2.62	1.75	2.85	1.49	1.79	0.97	2.85
Raw PDF	—	—	—	—	—	—	—	—

AKUMS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	737	837	1,162	1,287	1,444	1,312	1,349	1,409
Expenses	697	811	1,524	1,045	1,570	1,173	1,251	1,307
Operating Profit	40	27	-362	242	-126	139	98	102
OPM %	5%	3.2%	-31%	19%	-9%	11%	7%	7%
Other Income	66	-195	58	-48	74	124	106	104
Interest	4	1	4	13	18	15	10	10
Depreciation	25	26	28	30	33	40	46	48
Profit before tax	76	-195	-335	150	-103	208	148	148
Tax %	33%	-26%	14%	17%	61%	23%	25%	—
Net Profit	51	-145	-382	125	-165	161	112	112
EPS in Rs	3.56	-10.17	-26.68	8.77	-11.56	10.23	7.09	7.10
Dividend Payout %	0%	0%	0%	0%	0%	0%	41%	—

AKUMS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	1	1	1	14	29	29	31	31
Reserves	841	711	566	171	283	115	2,275	2,397
Borrowings	51	36	41	140	146	267	46	59
Other Liabilities	153	678	690	1,488	1,437	1,684	333	326
Total Liabilities	1,046	1,426	1,298	1,814	1,894	2,095	2,685	2,812
Fixed Assets	237	242	244	253	272	317	356	425
CWIP	0	1	1	1	16	9	57	52
Investments	4	65	149	141	139	139	366	366
Other Assets	806	1,118	903	1,419	1,466	1,631	1,906	1,969
Total Assets	1,046	1,426	1,298	1,814	1,894	2,095	2,685	2,812

AKUMS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	—	-22	56	228	94	248	91	-2
Cash from Investing Activity	—	-242	-100	-298	-202	-165	-459	-25
Cash from Financing Activity	—	302	3	95	90	-21	375	-3
Net Cash Flow	—	38	-42	25	-18	62	8	-30
Free Cash Flow	—	-53	27	200	-9	177	-3	-123
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	—	62%	226%	-65%	51%	-225%	101%	35%

AKUMS shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%
FIIs	6.36%	5.77%	4.24%	2.27%	1.14%	1.38%	1.91%	4.50%
DIIs	6.99%	7.39%	8.85%	9.28%	14.41%	14.36%	13.44%	11.09%
Public	8.64%	8.84%	8.92%	10.46%	6.45%	6.29%	6.67%	6.42%
Others	2.73%	2.73%	2.73%	2.73%	2.73%	2.73%	2.73%	2.73%
No. of Shareholders	68,410	69,366	69,424	75,365	76,869	72,589	70,289	67,618

AKUMS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	85	88	92	95	73	59	57	59
Inventory Days	93	96	67	85	91	68	92	101
Days Payable	60	85	63	120	82	69	100	89
Cash Conversion Cycle	118	99	96	61	82	58	49	71
Working Capital Days	103	121	89	-2	4	-11	47	67
ROCE %	14%	10%	8%	-71%	79%	-15%	16%	7%

AKUMSUpdated 18 Oct 2026, 5:03

Akums Drugs And Pharma L

AKUMSUpdated 18 Oct 2026, 5:03

Market Cap

₹11,513Cr.

Current Price

₹731

High / Low

₹839/409

Stock P/E

98.9

ROE4.92%

ROCE6.82%

Book Value₹154

Face Value₹2.00

Dividend Yield0.14%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	316	4	503	20	7	-178	6	-190	-13.26
Sep 2023	447	5	358	4	8	81	35	53	3.69
Dec 2023	383	5	351	25	8	43	32	29	2.05
Mar 2024	298	5	359	25	9	-49	18	-58	-4.05
Jun 2024	317	6	274	26	9	54	23	42	2.84
Sep 2024	328	4	285	32	9	62	18	50	3.2
Dec 2024	337	2	303	34	11	55	25	41	2.62
Mar 2025	329	3	311	32	10	37	26	28	1.75
Jun 2025	332	3	288	29	10	60	25	45	2.85
Sep 2025	309	2	292	27	11	31	25	23	1.49
Dec 2025	369	2	344	26	12	36	22	28	1.79
Mar 2026	338	3	327	25	12	22	30	15	0.97
Jun 2026	392	2	344	26	13	59	24	45	2.85

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2018	596	3	521	55	23	105	35	68	5.22
Mar 2019	683	4	603	58	23	112	33	75	5.77
Mar 2020	737	4	697	66	25	76	33	51	3.56
Mar 2021	837	1	811	-195	26	-195	-26	-145	-10.17
Mar 2022	1162	4	1524	58	28	-335	14	-382	-26.68
Mar 2023	1287	13	1045	-48	30	150	17	125	8.77
Mar 2024	1444	18	1570	74	33	-103	61	-165	-11.56
Mar 2025	1312	15	1173	124	40	208	23	161	10.23
Mar 2026	1349	10	1251	106	46	148	25	112	7.09
TTM	1409	10	1307	104	48	148	—	112	7.1

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	75.26%
FIIs	4.5%
DIIs	11.09%
Public	6.42%
Others	2.73%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public	Others
Sep 2024	75.26%	7.34%	7.53%	7.14%	2.73%
Dec 2024	75.26%	6.36%	6.99%	8.64%	2.73%
Mar 2025	75.26%	5.77%	7.39%	8.84%	2.73%
Jun 2025	75.26%	4.24%	8.85%	8.92%	2.73%
Sep 2025	75.26%	2.27%	9.28%	10.46%	2.73%
Dec 2025	75.26%	1.14%	14.41%	6.45%	2.73%
Mar 2026	75.26%	1.38%	14.36%	6.29%	2.73%
Jun 2026	75.26%	1.91%	13.44%	6.67%	2.73%
Sep 2026	75.26%	4.5%	11.09%	6.42%	2.73%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2018	1	766	33	160	960	236	0	4	720	960
Mar 2019	1	841	51	153	1046	237	0	4	806	1046
Mar 2020	1	711	36	678	1426	242	1	65	1118	1426
Mar 2021	1	566	41	690	1298	244	1	149	903	1298
Mar 2022	14	171	140	1488	1814	253	1	141	1419	1814
Mar 2023	29	283	146	1437	1894	272	16	139	1466	1894
Mar 2024	29	115	267	1684	2095	317	9	139	1631	2095
Mar 2025	31	2275	46	333	2685	356	57	366	1906	2685
Mar 2026	31	2397	59	326	2812	425	52	366	1969	2812

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2018	—	—	—	—
Mar 2019	—	—	—	—
Mar 2020	-22	-242	302	38
Mar 2021	56	-100	3	-42
Mar 2022	228	-298	95	25
Mar 2023	94	-202	90	-18
Mar 2024	248	-165	-21	62
Mar 2025	91	-459	375	8
Mar 2026	-2	-25	-3	-30

Key ratios

Historical financial ratios

Category	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	74	85	88	92	95	73	59	57	59
Inventory Days	123	93	96	67	85	91	68	92	101
Days Payable	87	60	85	63	120	82	69	100	89
Cash Conversion Cycle	110	118	99	96	61	82	58	49	71
Working Capital Days	109	103	121	89	-2	4	-11	47	67
ROCE %	—	14%	10%	8%	-71%	79%	-15%	16%	7%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of AKUMS DRUGS AND PHARMA L (AKUMS)?

The reported market capitalisation for AKUMS DRUGS AND PHARMA L (AKUMS) is ₹11,513Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of AKUMS?

The current price shown for AKUMS DRUGS AND PHARMA L (AKUMS) on Fincrux is ₹731 with a 52-week high/low of ₹839/409.

What is the P/E ratio of AKUMS DRUGS AND PHARMA L (AKUMS)?

The stock P/E for AKUMS DRUGS AND PHARMA L (AKUMS) is 98.9 on Fincrux, with ROE at 4.92% and ROCE at 6.82%.

What were AKUMS latest quarterly results?

For Jun 2026, AKUMS DRUGS AND PHARMA L (AKUMS) reported sales ₹392 Cr and net profit ₹45 Cr (figures in ₹ crore unless noted).

What are AKUMS annual sales and net profit?

For TTM, AKUMS DRUGS AND PHARMA L (AKUMS) shows sales of ₹1,409 Cr and net profit of ₹112 Cr on the Fincrux profit & loss statement.

Who owns AKUMS DRUGS AND PHARMA L (AKUMS)?

Latest shareholding for AKUMS DRUGS AND PHARMA L (AKUMS) on Fincrux: Promoters 75.26% (Sep 2026), FIIs 4.50% (Sep 2026), DIIs 11.09% (Sep 2026), Public 6.42% (Sep 2026), Others 2.73% (Sep 2026).

Where can I find AKUMS DRUGS AND PHARMA L (AKUMS) financials?

AKUMS DRUGS AND PHARMA L (AKUMS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show AKUMS balance sheet and cash flow?

Yes. The AKUMS DRUGS AND PHARMA L (AKUMS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 5:03